Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors

Author： Gore S.D.   Carducci M.A.  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.9, Iss.12, 2000-12, pp. : 2923-2934

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Histone deacetylase inhibitors in clinical development

By Rosato Roberto R   Grant Steven  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 1, 2004-01 ,pp. : 21-38

Informa Healthcare

Access to resources Recommend Favorite

A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials

By  

Current Pharmaceutical Design, Vol. 10, Iss. 19, 2004-07 ,pp. : 2289-2298

Bentham Science Publishers

Access to resources Recommend Favorite

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

By Marks Paul A  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 9, 2010-09 ,pp. : 1049-1066

Informa Healthcare

Access to resources Recommend Favorite

Recent Progress in the Development of Histone Deacetylase Inhibitors as Anti-Cancer Agents

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 14, 2013-12 ,pp. : 1999-2013

Bentham Science Publishers

Access to resources Recommend Favorite

Histone deacetylase inhibitors: from target to clinical trials

By Kelly William K   O’Connor Owen A   Marks Paul A  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 12, 2002-12 ,pp. : 1695-1713

Informa Healthcare

Access to resources Recommend Favorite